According to the official website of the State Food and Drug Administration, on February 1, the 2023 National Conference on Drug Registration Administration and Drug Post-market Supervision was held in Beijing. Huang Guo, a member of the Party Leadership Group and deputy director of the State Drug Administration, pointed out that we should continue to build a solid bottom line for drug safety, deepen the reform of the drug review and approval system, improve the efficiency of drug review and approval and supervision, and effectively ensure the safety, effectiveness and accessibility of drug use by the people. Huang Guo stressed that in 2023, drug registration management and post marketing supervision should achieve progress while maintaining stability in the five main lines of "epidemic prevention and control, risk resolution, innovative development, capacity improvement, and integrity building": do a good job in COVID-19 vaccine drug research and development services, emergency review and approval, quality supervision, and serve to ensure the overall situation of epidemic prevention and control; Strengthen the supervision of key varieties, key links and key areas, consolidate and expand the results of special rectification actions, and effectively prevent and eliminate potential safety risks; We will continue to deepen the reform of the review and approval system, speed up the listing of clinically urgently needed new drugs, drugs for rare diseases, and drugs for children, and innovate regulatory methods and means to promote high-quality development of the industry; We will improve the regulatory system, promote the electronic process of drug registration acceptance, review and approval, promote the standardized development of the drug inspection system, and improve regulatory efficiency; We will strengthen the construction of a clean and honest government, strengthen the anti-corruption mechanism, and severely punish violations of laws and disciplines, so as to provide a strong guarantee for the solid promotion of the modernization of drug supervision with Chinese characteristics. (Outlook New Era)